Comparison · NCT04331795-b123afca
Group A vs Group B: Survival to Hospital Discharge
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A vs Group B: Survival to Hospital Discharge. Trial comparisons, record NCT04331795-b123afca. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04331795-b123afca
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0833 | 0.0149 | 0.354 | wilson | |
| Risk in group 2 | 0.1 | 0.0279 | 0.301 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0167 | -0.229 | 0.263 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.833 | 0.0843 | 8.24 | log | |
| Odds ratio, group 1 over group 2 | 0.818 | 0.0662 | 10.1 | log | |
| Number needed to treat, for one fewer participant with the outcome on Group A than on Group B | 60 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A | Hospitalized, non-critically ill patients with COVID-19 pneumonitis with risk factors for decompensation~Tocilizumab: Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L | 1 | 12 | OG000 |
| Group 2 | Group B | Hospitalized, non-critically ill patients with COVID-19 pneumonitis without risk factors for decompensation~Tocilizumab: Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L | 2 | 20 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Survival to Hospital Discharge
- Description
This will be defined as the percentage of patients who are discharged in stable condition compared to the percentage of patients who die in the hospital. Patients who are discharged to hospice will be excluded from this calculation.
- Time frame
- Hospitalization, up to 4 weeks after tocilizumab administration
- Population
Source ClinicalTrials.gov
Trial
- Title
- Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis
- NCT number
- NCT04331795
- Phases
- PHASE2
- Conditions
- COVID-19
- Interventions
- Tocilizumab, Tocilizumab
- Lead sponsor
- University of Chicago
- Results first posted
- 2022-06-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04331795?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04331795-b123afca